Oric Pharmaceuticals, Inc. (ORIC) Stock Price & Analysis
Oric Pharmaceuticals, Inc. (ORIC) rose 11.11% to USD 12.1 as of July 25, 2026 at 01:46 UTC, according to Nexqual real-time market data.
ORIC last closed at USD 10.89; the session ranged USD 10.76–12.48 on volume of 3,609,571 shares. Market capitalization is $1.25B, with a 52-week range of USD 7.23–14.93 (NMS). Source: Nexqual, July 25, 2026 at 01:46 UTC.
Key Statistics (as of July 25, 2026 at 01:46 UTC)
| Price | USD 12.1 |
|---|---|
| Change | ▲ 11.11% (up) |
| Previous Close | USD 10.89 |
| Open | USD 10.94 |
| Day Range | USD 10.76 – 12.48 |
| 52-Week Range | USD 7.23 – 14.93 |
| Volume | 3,609,571 shares |
| Market Cap | $1.25B |
| Exchange | NMS |
Technical Analysis (ORIC)
Nexqual's technical model rates ORIC "BUY" based on 5 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 01:46 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 73.05 (overbought) |
| vs SMA50 | Above (USD 9.32) |
| MACD | 0.5 (positive) |
Analyst Ratings (ORIC)
Wall Street analysts rate ORIC "Strong Buy" based on 13 analysts, with a mean price target of USD 20.69 (range USD 14–25), per Nexqual as of July 25, 2026 at 01:46 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 20.69 |
| High Target | USD 25 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (ORIC)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.36 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.34 vs est -0.32 ▼ miss |
| 2025-12-31 | USD -0.3 vs est -0.37 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.4 ▲ beat |
| 2025-06-30 | USD -0.47 vs est -0.44 ▼ miss |
Source: Nexqual, July 25, 2026 at 01:46 UTC.
Financials & Fundamentals (ORIC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -42.57% |
| Debt / Equity | 1.62 |
| Current Ratio | 16.33 |
| Total Cash | $281.93M |
| Total Debt | $6.73M |
| Free Cash Flow | $-67.97M |
Source: Nexqual, July 25, 2026 at 01:46 UTC.
Financial Health Score (ORIC)
Nexqual rates Oric Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $282M cash vs $7M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$111M |
| Efficiency | Critical — ROE -43%, ROA -27.6% |
Ownership (ORIC)
| Insider Ownership | +5.85% |
|---|---|
| Institutional Ownership | +114.18% |
| Shares Outstanding | 103.52M |
| Float | 82.72M |
| Short % of Float | +21.58% |
Source: Nexqual, July 25, 2026 at 01:46 UTC.
Leadership (ORIC)
Oric Pharmaceuticals, Inc. is led by Jacob M. Chacko (age 46), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:46 UTC.
| President, CEO & Director | Jacob M. Chacko (age 46) |
|---|---|
| Founder, Independent Chairman & Member of Scientific Advisory Board | Richard A. Heyman (age 68) |
| Chief Financial Officer | Dominic G. Piscitelli (age 50) |
| Chief Scientific Officer | Lori Sickels Friedman (age 60) |
Major Backers & Investors (ORIC)
Notable institutional backers of Oric Pharmaceuticals, Inc. include Nextech Invest, Ltd., EcoR1 Capital, LLC, Viking Global, according to Nexqual as of July 25, 2026 at 01:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nextech Invest, Ltd. | 6.92% |
| EcoR1 Capital, LLC | 6.5% |
| Viking Global | 5.63% |
| Price (T.Rowe) Associates Inc | 5.2% |
| Pfizer Inc | 4.62% |
| SR One Capital Management, LP | 4.36% |
| Alkeon Capital Management LLC | 4.35% |
| Venrock Adviser, LLC | 4.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.3% |
Source: Nexqual, July 25, 2026 at 01:46 UTC.
From Oric Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.
- It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | USD 23.38 | ▼ 0.93% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 4.33 | ▼ 3.78% |
| OLMA | Olema Pharmaceuticals, Inc. | USD 11.7 | ▲ 1.83% |
| KROS | Keros Therapeutics, Inc. | USD 10.06 | ▼ 1.47% |
| CGEM | Cullinan Therapeutics, Inc. | USD 17.1 | ▼ 3.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:46 UTC. This page is informational and not investment advice.